Gilead to snap up liver disease biotech CymaBay for $4.3B

Gilead is betting $4.3 billion on a biotech six months before the FDA is expected to make an approval decision on its rare liver disease drug candidate.

The California big biotech will pay cash to buy CymaBay Therapeutics, the companies said Monday morning. The deal is for $32.50 per share,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks